Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lenalidomide, quantity: 7.5 mg - capsule - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; pregelatinised starch; sodium stearylfumarate; titanium dioxide; iron oxide yellow; gelatin; iron oxide black; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide - multiple myeloma (mm),lenalidomide viatris is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide viatris is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide viatris is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lenalidomide, quantity: 20 mg - capsule - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; sodium stearylfumarate; microcrystalline cellulose; pregelatinised starch; propylene glycol; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid; titanium dioxide; indigo carmine; iron oxide yellow; gelatin - multiple myeloma (mm),lenalidomide viatris is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide viatris is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide viatris is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lenalidomide, quantity: 2.5 mg - capsule - excipient ingredients: sodium stearylfumarate; croscarmellose sodium; microcrystalline cellulose; pregelatinised starch; colloidal anhydrous silica; titanium dioxide; indigo carmine; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide viatris is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide viatris is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide viatris is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 7.5 mg - capsule, hard - excipient ingredients: magnesium stearate; iron oxide black; gelatin; titanium dioxide; shellac; croscarmellose sodium; potassium hydroxide; microcrystalline cellulose; lactose monohydrate; iron oxide yellow; purified water - multiple myeloma (mm),lenalidomide ran is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide ran is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide ran is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 7.5 mg - capsule, hard - excipient ingredients: potassium hydroxide; gelatin; titanium dioxide; microcrystalline cellulose; iron oxide yellow; croscarmellose sodium; lactose monohydrate; iron oxide black; magnesium stearate; shellac - multiple myeloma (mm),lenalidomide rbx is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide rbx is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide rbx is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 7.5 mg - capsule, hard - excipient ingredients: gelatin; iron oxide black; shellac; titanium dioxide; microcrystalline cellulose; lactose monohydrate; magnesium stearate; croscarmellose sodium; potassium hydroxide; iron oxide yellow; purified water - multiple myeloma (mm),lenalidomide sun is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sun is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sun is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 5 mg - capsule, hard - excipient ingredients: shellac; gelatin; microcrystalline cellulose; titanium dioxide; magnesium stearate; croscarmellose sodium; iron oxide black; potassium hydroxide; lactose monohydrate; purified water - multiple myeloma (mm),lenalidomide ran is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide ran is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide ran is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 5 mg - capsule, hard - excipient ingredients: gelatin; microcrystalline cellulose; shellac; potassium hydroxide; croscarmellose sodium; titanium dioxide; iron oxide black; magnesium stearate; lactose monohydrate; purified water - multiple myeloma (mm),lenalidomide rbx is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide rbx is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide rbx is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 5 mg - capsule, hard - excipient ingredients: gelatin; shellac; croscarmellose sodium; potassium hydroxide; microcrystalline cellulose; iron oxide black; titanium dioxide; lactose monohydrate; magnesium stearate; purified water - multiple myeloma (mm),lenalidomide sun is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sun is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sun is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lenalidomide, quantity: 25 mg - capsule, hard - excipient ingredients: lactose monohydrate; iron oxide black; titanium dioxide; gelatin; croscarmellose sodium; shellac; microcrystalline cellulose; potassium hydroxide; magnesium stearate; purified water - multiple myeloma (mm),lenalidomide ran is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide ran is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide ran is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.